Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,627 signal articles · 44 in last 24h · 155,673 total before filter · latest 2h ago
44last 24h
846last 7d
141● bullish (7d)
89● bearish (7d)
214publishers
AllMacro196Earnings105M&A122Regulatory20Product21Analyst19
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Magnificent Seven Hit All Time High
24/7 Wall St.4d agoneutral
Magnificent Seven Hit All Time High

After a brutal early 2026 selloff that left the most powerful stocks in the market looking finished, something shifted. The forces that once drove the biggest rally in stock market history may be waking back up.

Workday (WDAY): Buy, Sell, or Hold Post Q2 Earnings?
StockStory4d agoneutral
Workday (WDAY): Buy, Sell, or Hold Post Q2 Earnings?

What a time it’s been for Workday. In the past six months alone, the company’s stock price has increased by a massive 40.1%, reaching $192.03 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

3M’s CEO Says the Turnaround Is Ahead of Schedule, But PFAS Litigation Keeps Resurfacing
Insider Monkey4d agoneutral
3M’s CEO Says the Turnaround Is Ahead of Schedule, But PFAS Litigation Keeps Resurfacing

3M Company (NYSE:MMM) CEO William Brown has told investors that the company’s operational turnaround is progressing ahead of its own targets. New product activity is expanding, delivery performance has improved, margins are moving higher, and the data-center opportunity tied to its Microsoft partnership is growing rapidly. Together, these metrics provide a detailed picture of improving […]

Why Is Merck (MRK) In Focus After Japan Cleared A New Dosing Option?
Simply Wall St.4d agoneutral
Why Is Merck (MRK) In Focus After Japan Cleared A New Dosing Option?

Merck (NYSE:MRK) received Japanese approval for KEYTRUDA QLEX (KEYJECT), its first subcutaneous KEYTRUDA formulation, for all existing local indications. The new subcutaneous version offers an alternative to intravenous dosing, aimed at faster administration for patients and clinicians. This approval broadens Merck's oncology treatment options in Japan, a key international market for its immunotherapy portfolio. The KEYTRUDA QLEX subcutaneous green light in Japan matters. However, investors...

NuScale Power (SMR) Draws Fresh Attention, Is The Stock Still A Bargain?
Simply Wall St.4d agoneutral
NuScale Power (SMR) Draws Fresh Attention, Is The Stock Still A Bargain?

Why NuScale Power Is Back in the Spotlight NuScale Power (SMR) is drawing fresh attention as investors reassess nuclear backed grid capacity for energy hungry AI data centers, with the stock trading near US$8.79 as of 21 September 2026. The business has advanced regulatory and engineering work, including projects in Romania and ongoing talks with the Tennessee Valley Authority. Its current backlog remains largely non binding, and first reactor deployments are not expected until the early...

Jim Cramer Praises OKTA for Tackling AI Security Threats
Insider Monkey4d agoneutral
Jim Cramer Praises OKTA for Tackling AI Security Threats

During the September 18 episode of CNBC’s Mad Money, Jim Cramer highlighted Okta, Inc. (NASDAQ:OKTA) after speaking with technology leaders in Silicon Valley. He stated: Let’s start with the most consequential. On Wednesday, we have an Okta analyst, okay? This is it. Of all the companies I had on the show this past week in […]

3 Consumer Stocks We Steer Clear Of
StockStory4d agoneutral
3 Consumer Stocks We Steer Clear Of

Consumer discretionary businesses are levered to the highs and lows of economic cycles. Over the past six months, it seems like demand may be facing some headwinds as the industry’s 1.8% return has lagged the S&P 500 by 14.5 percentage points.

This Power Parts Maker’s Stock Has Gained 316% in 2026. It’s Rising Again Today on Boost to Growth Guidance.
Barrons.com4d agoneutral
This Power Parts Maker’s Stock Has Gained 316% in 2026. It’s Rising Again Today on Boost to Growth Guidance.

Power electronics company Vicor jumped Tuesday after nearly doubling its sequential revenue growth guidance, driven by royalty fees from a new patent license deal for its artificial-intelligence-power technology. Vicor raised its sequential revenue growth forecast for the fiscal third quarter to more than 20%, up from its previous 10% projection, the company said in press release. Vinciarelli added that the clients approached Vicor after realizing that using unlicensed power delivery components put their AI computing systems at risk of import bans from the U.S. International Trade Commission and patent infringement litigation.

Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline
MarketBeat4d agoneutral
Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline

Pfizer (NYSE:PFE) has rebuilt its commercial model around newer and acquired products while reducing exposure to its COVID-19 franchise, according to Alexandre de Germay, the company’s chief international commercial officer and executive vice president. Speaking with Chris Schott at a company event